Los Angeles Biotechnology Network
Advertise With Biotech Networks
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ September 26, 2023 ] Muscle Lab Ignites a Wellness Evolution with the Launch of GPT-4 Driven Custom Recovery Plans and Smart Lab Los Angeles Biotech News
  • [ September 26, 2023 ] Herbalife Steps Up to Support Healthy Active Lifestyles for 10th Consecutive Year as Nutrition Partner for Downtown Los Angeles YMCA’s Stair Climb & Urban Hike Los Angeles Biotech News
  • [ September 26, 2023 ] CLININICAL LAB SCIENTIST I – PD – IRVINE HEMATOLOGY – Hoag Memorial Hospital Presbyterian – Irvine, CA Los Angeles Biotech Jobs
  • [ September 26, 2023 ] How TikTok’s algorithm and audiences are finally convincing Big Pharma to join Los Angeles Biotech News
  • [ September 26, 2023 ] Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline Los Angeles Biotech News
HomeLos Angeles Biotech NewsRoche’s KRAS data suggest potential edge over Amgen and Mirati, but the jury remains out

Roche’s KRAS data suggest potential edge over Amgen and Mirati, but the jury remains out

August 24, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Roche’s KRAS data suggest potential edge over Amgen and Mirati, but the jury remains out

Roche’s KRAS data suggest potential edge over Amgen and Mirati, but the jury remains out
ntaylor
Thu, 08/24/2023 – 09:50
Click here to view original post

Previous

Scientist II, In vitro Pharmacology – ABBVIE – Irvine, CA

Next

Susan G. Komen® Hosts Annual 2023 Orange County MORE THAN PINK Walk

Follow/Subscribe

Advertise With Biotech Networks
POST A JOB
Tweets by LABioNetwork
Advertise With Biotech Networks

Copyright © 2023 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered